ASP2074
Phase 1Terminated 1 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Tumors
Conditions
Advanced Solid Tumors
Trial Timeline
Feb 28, 2023 → Oct 17, 2024
NCT ID
NCT05646797About ASP2074
ASP2074 is a phase 1 stage product being developed by Astellas Pharma for Advanced Solid Tumors. The current trial status is terminated. This product is registered under clinical trial identifier NCT05646797. Target conditions include Advanced Solid Tumors.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Solid Tumors were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05646797 | Phase 1 | Terminated |
Competing Products
20 competing products in Advanced Solid Tumors